Key Highlights

  • Net income for the third quarter of 2026 was USD 1.35 million, against a net loss of USD 18.4 million a year earlier, and income from operations was USD 5.8 million.
  • RYTELO net product Revenue was USD 60.1 million versus USD 47.2 million, up 27% year over year and 5% from the prior quarter, according to management.
  • Operating expenses excluding Cost of Goods Sold fell to USD 48.3 million from USD 60.1 million, and 2026 Operating Expense guidance was lowered to USD 220 million to USD 230 million.
  • Cash, cash equivalents, restricted cash and marketable securities were about USD 339.4 million at September 30, 2026, while the Phase 3 IMpactMF trial was discontinued in October.

RYTELO Sales Deliver a First Profitable Quarter in Years

Geron (NASDAQ:GERN) filed its Quarterly Report and held its Earnings Call on November 4, 2026. Total revenue was USD 60.2 million, almost all net RYTELO product revenue of USD 60.1 million. Income from operations reached USD 5.8 million versus a USD 13.9 million loss, and Net Income was USD 1.35 million, or USD 0.00 per share. The filing says the company has reported no profit since 2015 other than this quarter, and cautions that its ability to stay profitable is uncertain. Nine-month net loss was USD 19.0 million against USD 54.6 million.

Demand Growth and Lower Costs Drive the Swing

RYTELO, a telomerase inhibitor for lower-risk myelodysplastic syndromes, saw 10% quarter-over-quarter Demand growth, and prescribing accounts rose 8% to more than 1,700 since launch, said management. Gross-to-net deductions eased to 19.3% from 21.6%. Research and Development expense fell to USD 12.7 million from USD 21.1 million, and selling, general and administrative expense to USD 35.7 million from USD 39.0 million, partly because of a December 2025 workforce reduction. Cost of goods sold rose to USD 6.1 million from USD 1.0 million, including USD 4.8 million of non-cash inventory write-offs. Interest expense was USD 7.2 million.

Myelofibrosis Trial Ends, Europe Launch Begins

In October 2026, Geron discontinued the Phase 3 IMpactMF trial in relapsed or refractory myelofibrosis after an independent monitoring committee concluded it was unlikely to meet its overall survival endpoint, with no new safety signals. The company says it cannot pursue approval in that indication and will not recoup the investment, and it remains wholly dependent on RYTELO. A gated European launch aims for availability in Germany by the end of 2026 and in France in 2027. Management reiterated 2026 net revenue guidance of USD 220 million to USD 240 million, expecting the mid to high end, and expects some operating expense increases in 2027.

Where Things Stand

The profit came from commercial growth and cost cuts, not from any pipeline success. Geron (NASDAQ:GERN) turned a USD 13.9 million operating loss into a USD 5.8 million operating profit as RYTELO revenue rose 27% and operating costs fell, but the myelofibrosis trial stop was announced about a week before the report. Net income of USD 1.35 million is thin, and 2027 spending will rise with Europe and post-marketing commitments. Watch the fourth-quarter revenue against the mid to high end of guidance and the detailed IMpactMF data analysis. No share price reaction appears in the filing.